The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDCX | -52.94% | N/A | N/A | -71% |
| S&P | +15.4% | +78.67% | +12.31% | +41% |
Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. It focuses on identifying, acquiring, and advancing relatively de-risked clinical stage assets through clinical development and commercialization. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.
No news articles found for Medicus Pharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 100.0% |
| Market Cap | $27.36M | -27.5% |
| Market Cap / Employee | $2.28M | 0.0% |
| Employees | 12 | 0.0% |
| Net Income | -$15,981.31K | -440.1% |
| EBITDA | -$6,708.87K | -125.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.66M | 63.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $124.65K | -47.3% |
| Short Term Debt | $6.93M | 6063.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -368.01% | -169.5% |
| Return On Invested Capital | -406.06% | 176.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6,832.07K | -122.0% |
| Operating Free Cash Flow | -$6,832.07K | -122.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.55 | 14.02 | 18.68 | 11.36 | 5.06% |
| Price to Tangible Book Value | 7.55 | 14.02 | 18.68 | 11.36 | -2.96% |
| Enterprise Value to EBITDA | -8.74 | -8.16 | -6.32 | -6.20 | -11.50% |
| Return on Equity | -695.3% | -1797.7% | -327.1% | -2237.5% | 628.58% |
| Total Debt | $224.08K | $294.69K | $4.97M | $7.05M | 1920.66% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
